Utah Medical Q2 Revenue Plunges 14% as Key Customers Vanish
UTMD sits 29% above its 52-week low of $53.66 on elevated volume (3.7× avg).
Summary
Utah Medical Products reported Q2 revenue down 14% year-over-year to $8.53 million, driven by the loss of its two largest customers. Diluted EPS fell 10% to $0.84, with higher litigation costs and a slight gross margin contraction adding pressure. New biopharma OEM sales have been negligible—just $211 in the first half—failing to offset the lost business. Management now expects full-year 2026 sales to decline 10–13% and litigation expenses under $1.6 million, but warns of substantial uncertainty. This follows a Q1 that already showed a 10% revenue drop, confirming a deepening trend. The stock may face further pressure as the market digests the lack of replacement customers and the grim outlook.
At the time of this announcement, UTMD was trading at $69.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $220.3M. The 52-week trading range was $53.66 to $75.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.